Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when PSTV files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsPlus Therapeutics holds routine annual meeting, approves stock plan amendment
Filed May 15, 2026 · Period ending May 14, 2026 · ~1 min read
Key Changes
-
medium
Stockholders approved the sixth amendment to the 2020 Stock Incentive Plan, the most contested item with 7.98M votes for versus 5.65M against, potentially increasing shares available for employee compensation.
Item 5.07 verify on EDGAR → -
low
Six directors elected to one-year terms through 2027 annual meeting: Howard Clowes, An van Es-Johansson, Richard Hawkins, Marc Hedrick, Ronald Andrews, and Kyle Guse.
Item 5.07 verify on EDGAR → -
low
Stockholders ratified CBIZ CPAs as independent auditor for fiscal 2026 with 60.86M votes for, representing routine governance approval.
Item 5.07 verify on EDGAR → -
low
Meeting had quorum with 64.86M shares represented, approximately 38% of the 171.55M shares outstanding as of March 18, 2026 record date.
Item 5.07 verify on EDGAR →
Summary
Plus Therapeutics held its 2026 Annual Meeting on May 14, where stockholders voted on standard governance matters. The most notable item was approval of the sixth amendment to the company's 2020 Stock Incentive Plan, which passed but drew the most opposition with roughly 41% of votes cast against it.
This amendment likely expands the share pool available for employee equity compensation, which could mean future dilution for existing shareholders. All six director nominees were re-elected to one-year terms, and the independent auditor was ratified with strong support. Voter turnout was modest at 38% of outstanding shares, typical for small-cap biotechnology companies.
Retail investors should watch for details on the stock plan amendment in upcoming SEC filings to understand the extent of potential dilution. The next catalyst will likely be operational updates on the company's therapeutic pipeline rather than governance matters.
Section-by-Section Diff
Event · Item 5.07 — Submission of Matters to a Vote of Security Holders
Plus Therapeutics held its 2026 Annual Meeting on May 14, 2026, where stockholders elected six directors and approved routine matters.
Show 2 minor / wording changes
Added in current filing · verify on EDGAR → · paraphrased
The Company's stockholders elected the following persons, who were listed in the Proxy Statement, to the Board of Directors of the Company (the "Board") to hold office for a term expiring at the Company's Annual Meeting of Stockholders in 2027 and until each such person's successors is duly elected and qualified, or until his or her earlier death, resignation or removal: Howard Clowes, An van Es-Johansson, M.D., Richard J. Hawkins, Marc H. Hedrick, M.D., Ronald A. Andrews, Kyle Guse, Esq., MBA, CPA
Six directors were elected to serve one-year terms expiring at the 2027 annual meeting. All nominees received between 11.8 million and 12.4 million votes for, with approximately 1.6 to 2.2 million votes withheld.
Added in current filing · verify on EDGAR →
The Company’s stockholders ratified the appointment of CBIZ CPAs, P.C. as the Company’s independent registered public accounting firm for the 2026 fiscal year.
Stockholders ratified CBIZ CPAs, P.C. as the independent auditor for fiscal 2026, with 60,860,051 votes for, 2,292,062 against, and 1,705,208 abstentions.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 8, 2026 · How we verify